CN108697688A - 用于治疗多汗症的方法和组合物 - Google Patents

用于治疗多汗症的方法和组合物 Download PDF

Info

Publication number
CN108697688A
CN108697688A CN201680082300.6A CN201680082300A CN108697688A CN 108697688 A CN108697688 A CN 108697688A CN 201680082300 A CN201680082300 A CN 201680082300A CN 108697688 A CN108697688 A CN 108697688A
Authority
CN
China
Prior art keywords
acceptable salt
pharmaceutically acceptable
subject
composition
ephidrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680082300.6A
Other languages
English (en)
Chinese (zh)
Inventor
本杰明·F·麦格劳三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theravida Inc
Original Assignee
Theravida Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravida Inc filed Critical Theravida Inc
Publication of CN108697688A publication Critical patent/CN108697688A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Dermatology (AREA)
CN201680082300.6A 2016-01-20 2016-01-20 用于治疗多汗症的方法和组合物 Pending CN108697688A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2016/014150 WO2017127073A1 (en) 2016-01-20 2016-01-20 Methods and compositions for treating hyperhidrosis

Publications (1)

Publication Number Publication Date
CN108697688A true CN108697688A (zh) 2018-10-23

Family

ID=59314209

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680082300.6A Pending CN108697688A (zh) 2016-01-20 2016-01-20 用于治疗多汗症的方法和组合物

Country Status (15)

Country Link
US (4) US10328057B2 (https=)
EP (1) EP3405191B1 (https=)
JP (1) JP6841834B2 (https=)
KR (2) KR102600541B1 (https=)
CN (1) CN108697688A (https=)
AU (2) AU2016388308B2 (https=)
BR (1) BR112018014661A2 (https=)
CA (1) CA3011683C (https=)
DK (1) DK3405191T3 (https=)
HK (1) HK1258825A1 (https=)
MX (1) MX394356B (https=)
RU (1) RU2718906C2 (https=)
TW (2) TW202341976A (https=)
WO (1) WO2017127073A1 (https=)
ZA (1) ZA201805490B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis
KR102408292B1 (ko) 2018-09-28 2022-06-10 카루나 세러퓨틱스 인코포레이티드 무스카린성 수용체 활성화에 의해 개선된 장애의 치료를 위한 조성물 및 방법
EP3993646B1 (en) 2019-07-05 2023-08-16 Swedish Match North Europe AB An oral pouched nicotine product including a filling material comprising nicotine-containing particles
PL4115746T3 (pl) 2019-11-20 2024-01-29 Swedish Match North Europe Ab Doustny produkt nikotynowy w saszetce, zawierający materiał wypełniający obejmujący cząstki nikotyny
EP3967311A1 (en) * 2020-09-11 2022-03-16 Astellas Pharma Inc. Compounds for use in the treatment of dry mouth
EP4018849B1 (en) 2020-12-22 2024-10-23 Swedish Match North Europe AB A pouched product for oral use
PL4018848T3 (pl) 2020-12-22 2024-11-25 Swedish Match North Europe Ab Wyrób w saszetkach do użytku doustnego zawierający materiał pokrywający przepuszczalny dla cieczy oraz materiał wypełniający
EP4018847B1 (en) 2020-12-22 2024-09-18 Swedish Match North Europe AB A pouched product for oral use
CA3228464A1 (en) * 2021-08-11 2023-02-16 Theravida, Inc. Pharmaceutical compositions and methods for treating hyperhidrosis
TR2023000985A2 (tr) * 2023-01-27 2023-02-21 Ardi Farma Ilac Pazarlama Ticaret Ltd Sirketi Kontrollü salim sağlayan propi̇veri̇n formülasyonu

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287462A (zh) * 2005-09-02 2008-10-15 塞拉维达公司 治疗疾病的疗法
CN101340884A (zh) * 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
CN103228267A (zh) * 2010-04-01 2013-07-31 塞拉维达公司 治疗膀胱过动症的药物制剂

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4209505A (en) 1979-04-03 1980-06-24 Mikhail Adib R Pilocarpine mouthwash for dry mouth relief
US4302440B1 (en) * 1980-07-31 1986-08-05 Easily-swallowed, powder-free and gastric-disintegrable aspirin tablet thinly-coated with hydroxypropyl methylcellulose and aqueous spray-coating preparation thereof
SE450087B (sv) 1985-10-11 1987-06-09 Haessle Ab Korn med kontrollerad frisettning av farmaceutiskt aktiva emnen som anbringats teckande pa ett kompakt olosligt kernmaterial
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
EP0746310B1 (en) 1994-02-23 1998-11-18 BM Research A/S Controlled release composition
US5674895A (en) 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
EP0951279A1 (en) 1997-01-10 1999-10-27 Abbott Laboratories Tablet for the controlled release of active agents
JP3608800B2 (ja) * 1997-03-26 2005-01-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗真菌剤およびポリマーでコートされたコアを有するペレット剤
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
US6482837B1 (en) 1998-04-24 2002-11-19 University Of Rochester Antimuscarinic compounds and methods for treatment of bladder diseases
US5997905A (en) 1998-09-04 1999-12-07 Mcneil-Ppc Preparation of pharmaceutically active particles
EP1125586A4 (en) 1998-10-26 2003-06-11 Tanabe Seiyaku Co EXTENDED RELEASE PARTICLE
FR2795962B1 (fr) 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
CN100391438C (zh) 1999-09-14 2008-06-04 史密丝克莱恩比彻姆公司 制备水性包被小球粒的方法
NZ518309A (en) 1999-11-11 2003-05-30 Pharmacia Ab Controlled release tolterodine formulation that releases not less than 80% of the active compound in under 18 hours
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DE60322371D1 (de) 2002-03-29 2008-09-04 Alza Corp Volumensparende arzneiform zur kontrollierten freisetzung
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
US9107804B2 (en) 2002-12-10 2015-08-18 Nortec Development Associates, Inc. Method of preparing biologically active formulations
EP1635795A1 (en) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Controlled release pharmaceutical compositions of tolterodine and processes for their preparation
WO2005013939A1 (en) 2003-08-06 2005-02-17 Nirmal Mulye Pharmaceutical composition containing water soluble drug
DK2210605T3 (en) 2003-11-04 2017-05-22 Tcd Royalty Sub Llc Daily single dose doses of trospium.
CA2579767A1 (en) 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
US20080254115A1 (en) 2004-05-19 2008-10-16 Rubino Orapin P Micropellet Containing Pellets and Method of Preparing Such Pellets
US20070224269A1 (en) 2004-06-10 2007-09-27 Rubino Orapin P Controlled Release Pharmaceutical Formulation
JP2008516893A (ja) 2004-08-27 2008-05-22 スフェリックス，インク． 多層錠剤および生体接着性剤形
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
WO2007029087A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Controlled release multiple unit formulations
US20070077300A1 (en) 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20100086592A1 (en) 2007-03-29 2010-04-08 Panacea Biotec Limited. Modified dosage forms of tacrolimus
US7563508B2 (en) 2007-05-30 2009-07-21 Chung Shan Institute Of Science And Technology, Armaments Bureau, M.N.D. Diffusion beads with core-shell structure
EP2173329A1 (en) 2007-07-03 2010-04-14 Synthon B.V. Tolterodine bead
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
WO2009019599A2 (en) 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
US9561015B2 (en) * 2007-08-24 2017-02-07 General Electric Company Method and apparatus for voice recording with ultrasound imaging
EP2205279B1 (en) 2007-09-28 2011-04-13 Novartis AG Pharmaceutical combination of aliskiren and valsartan
WO2009057138A2 (en) 2007-10-29 2009-05-07 Lupin Limited Controlled release pharmaceutical compositions of tolterodine
US20090192228A1 (en) 2008-01-28 2009-07-30 Actavis Group Ptc Ehf Controlled-Release Tolterodine Compositions and Methods
US20090247628A1 (en) * 2008-03-25 2009-10-01 Auspex Pharmaceuticals, Inc. Substituted phenylcyclohexylglycolates
CN102939008A (zh) 2010-04-01 2013-02-20 塞拉维达公司 改善睡眠质量的方法
RU2671575C2 (ru) 2011-05-10 2018-11-02 Теравида, Инк. Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
US20140037713A1 (en) * 2012-08-03 2014-02-06 Antares Pharma Ipl, Ag Transdermal compositions for anti-cholinergic agents
JP2015533174A (ja) 2012-10-11 2015-11-19 セラヴィダ，インコーポレイテッド ピロカルピンの医薬製剤
WO2017127073A1 (en) 2016-01-20 2017-07-27 Theravida, Inc. Methods and compositions for treating hyperhidrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101287462A (zh) * 2005-09-02 2008-10-15 塞拉维达公司 治疗疾病的疗法
CN101340884A (zh) * 2005-10-19 2009-01-07 曼尼·马纳舍·辛格尔 用于治疗多汗症的方法
CN103228267A (zh) * 2010-04-01 2013-07-31 塞拉维达公司 治疗膀胱过动症的药物制剂

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DR JANAKAN KRISHNARAJAH: "ACTRN12615000873527: A phase 2a stydy evaluating the safety and efficacy of thvd-102, a combination of Oxybutynin and pilocarpine, in subjects with primary focal hyperhidrosis", 《HTTPS://WWW.ANZCTR.ORG.AU/TRIAL/REGISTRATION/TRIALREVIEW.ASPX?ACTRN=12615000873527》 *

Also Published As

Publication number Publication date
KR20230021184A (ko) 2023-02-13
HK1258825A1 (zh) 2019-11-22
MX394356B (es) 2025-03-24
US20200188360A1 (en) 2020-06-18
AU2022206709A1 (en) 2022-08-11
EP3405191B1 (en) 2025-02-19
RU2018128047A (ru) 2020-02-20
CA3011683C (en) 2023-09-26
US20170202778A1 (en) 2017-07-20
AU2016388308B2 (en) 2022-08-04
EP3405191A4 (en) 2019-09-04
KR102600541B1 (ko) 2023-11-08
RU2718906C2 (ru) 2020-04-15
RU2018128047A3 (https=) 2020-02-20
TWI810150B (zh) 2023-08-01
MX2018008694A (es) 2019-05-15
TW201737906A (zh) 2017-11-01
US20220047558A1 (en) 2022-02-17
EP3405191A1 (en) 2018-11-28
CA3011683A1 (en) 2017-07-27
JP6841834B2 (ja) 2021-03-10
US11779569B2 (en) 2023-10-10
KR20180102649A (ko) 2018-09-17
BR112018014661A2 (pt) 2018-12-11
ZA201805490B (en) 2019-11-27
US10328057B2 (en) 2019-06-25
DK3405191T3 (da) 2025-05-19
JP2019506401A (ja) 2019-03-07
TW202341976A (zh) 2023-11-01
US20190307727A1 (en) 2019-10-10
WO2017127073A1 (en) 2017-07-27
US10610519B2 (en) 2020-04-07
US11185533B2 (en) 2021-11-30
AU2016388308A1 (en) 2018-08-02
KR102495757B1 (ko) 2023-02-06

Similar Documents

Publication Publication Date Title
US11779569B2 (en) Methods and compositions for treating hyperhidrosis
KR102444608B1 (ko) 불면증을 치료하기 위한 조성물 및 방법
CN115348862A (zh) 用于复发型多发性硬化症(rms)的治疗性酪氨酸激酶抑制剂
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
AU2013344281A1 (en) Pharmaceutical compositions comprising hydromorphone and naloxone
Troy et al. Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers
ES3047794T3 (en) Tablet for use in treating huntington's disease and method of making the same
HK1261838A1 (en) Methods and compositions for treating hyperhidrosis
US20240350420A1 (en) Pharmaceutical compositions and methods for treating hyperhidrosis
JP2002507566A (ja) 口内乾燥症を低減させるオキシブチニン徐放性組成物
US20190160030A1 (en) Carboxylic acids for early childhood application
WO2015143548A1 (en) Reducing drug liking in a subject
HK40003409A (en) Treatment of prurigo nodularis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1261838

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20181023

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1261838

Country of ref document: HK